S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY
暂无分享,去创建一个
H. Einsele | E. Rasmussen | J. Kalabus | P. Moreau | C. Langer | G. Zugmaier | T. Facon | K. Beutner | M. Attal | R. Lesley | K. Riemann | G. Munzert | M. Topp | J. Duell | A. Minella | J. Kroenke | A. Salnikov